Mizuki Nishino.

All analyses were performed with the use of SAS software, version 9.1 . Outcomes Characteristics of the analysis Participants Of the 2508 participants recruited originally, 2416 had an HRCT scan available and were included in this analysis. Of the 2416 participants, 1171 were women, 613 were black, 1060 were energetic smokers, and 1002 met the GOLD requirements for COPD. Of the 2416 HRCT scans evaluated, 194 showed interstitial lung abnormalities, 861 had been indeterminate, and 1361 didn’t present interstitial lung abnormalities .Statistical Analysis We performed a noninferiority analysis for the principal end point. Based on FDA guidance, we selected a noninferiority margin of 4.20 We estimated that the assignment of 2000 patients in a 2:1 ratio to the Absorb group versus the Xience group would provide a power of 96 percent to demonstrate noninferiority, assuming an interest rate of target-lesion failure of 7.0 percent with both products with a one-sided alpha level of 0.025 and a 5 percent loss to follow-up.